{
    "clinical_study": {
        "@rank": "65273", 
        "arm_group": [
            {
                "arm_group_label": "Paclitaxel plus Reolysin", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel given weekly on days 1, 8, 15 every 4 weeks plus reolysin days 1, 2, 8, 9, 15 and 16."
            }, 
            {
                "arm_group_label": "Paclitaxel", 
                "arm_group_type": "Active Comparator", 
                "description": "Paclitaxel given weekly on days 1, 8 and 15 every 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Researchers doing this study want to evaluate the side effects of Reolysin when given\n      together with paclitaxel. As these drugs have not been given together before, 6-9 patients\n      will be treated with paclitaxel plus reolysin to ensure that side effects are tolerable."
        }, 
        "brief_title": "A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The purpose of the randomized part of this study is to find out if giving Reolysin in\n      combination with paclitaxel can offer better results than standard therapy with paclitaxel."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have a histological/cytological diagnosis of metastatic breast cancer.\n\n          -  Patients must have advanced and/or metastatic disease, for which no curative therapy\n             exists and for which systemic therapy is indicated.\n\n          -  All patients must have an available formalin fixed paraffin embedded tissue block\n             (from their primary or metastatic tumour) and must have provided informed consent for\n             the release of the block, as well as for CTC and blood samples for correlative\n             studies and banking.\n\n        For patients who have not had a tissue biopsy within the last 12 months, a repeat biopsy\n        is strongly recommended but is not mandated providing that archival tissue is available.\n\n        \u2022 Re-biopsy is recommended if > 1 year since last biopsy.\n\n          -  Presence of clinically and/or radiologically documented disease. All radiology\n             studies must be performed within 28 days prior to randomization (within 35 days if\n             negative).\n\n        All patients must have measurable disease as defined by RECIST 1.1.\n\n        The criteria for defining measurable disease are as follows:\n\n        Chest xray \u2265 20mm CT/MRI scan (with slice thickness <5mm) \u226510mm -> longest diameter\n        Physical exam (using calipers) \u2265 10mm Lymph nodes by CT scan \u2265 15mm -> measured in short\n        axis\n\n          -  ECOG performance of 0, 1 or 2.\n\n          -  Age \u2265 18 years of age\n\n          -  Previous Therapy\n\n        Surgery:\n\n        Previous major surgery is permitted provided that it has been at least 21days prior to\n        patient randomization and that wound healing has occurred.\n\n        Chemotherapy:\n\n        Patients must have received at least one prior chemotherapy regimen for advanced or\n        metastatic disease unless:\n\n          1. they have relapsed within 6 months of completion of adjuvant chemotherapy or\n\n          2. they have received taxane and/or anthracycline containing adjuvant chemotherapy\n             Palliative therapy for breast cancer (chemotherapy, targeted, hormonal) is permitted\n             but no more than three prior chemotherapy regimens are permissible.\n\n        Other Therapy:\n\n        Patients may have received other therapies including immunotherapy, or with signal\n        transduction inhibitors.\n\n        Patients must have recovered from all reversible toxicity related to prior chemotherapy\n        and have adequate washout from prior chemotherapy, and investigational agents as follows:\n\n        longest of one of the following.\n\n          -  two weeks\n\n          -  standard cycle length of prior regimen (i.e 21 days for doxorubicin q3 weeks)\n\n          -  5 half-lives for investigational drugs.\n\n        Radiation:\n\n        Prior external beam radiation is permitted provided a minimum of 4 weeks has elapsed\n        between the last dose and enrollment to the trial. Exceptions may be made for low dose,\n        non-myelosuppressive radiotherapy after consultation with NCIC CTG.\n\n          -  Laboratory Requirements (must be done within 7 days prior to randomization)\n\n        Hematology:\n\n        Granulocytes (AGC) \u2265 1.5 x 10^9/L Platelets \u2265 100 x 10^9/L\n\n        Biochemistry:\n\n        Serum creatinine \u2264 1.5 x ULN Total bilirubin \u2264 1.0 x ULN (unless elevated secondary to\n        conditions such as Gilbert's disease) ALT and AST \u2264 3 x ULN (Note: \u2264 5 x ULN if documented\n        liver metastasis)\n\n          -  Patient consent must be appropriately obtained in accordance with applicable local\n             and regulatory requirements. Each patient must sign a consent form prior to\n             enrollment in the trial to document their willingness to participate.\n\n        Patients who cannot give informed consent (i.e. mentally incompetent patients, or those\n        physically incapacitated such as comatose patients) are not to be recruited into the\n        study. Patients competent but physically unable to sign the consent form may have the\n        document signed by their nearest relative or legal guardian. Each patient will be provided\n        with a full explanation of the study before consent is requested.\n\n          -  Patients must be accessible for treatment and follow-up. Patients registered on this\n             trial must be treated and followed at the participating centre. This implies there\n             must be reasonable geographical limits (for example: 2 hour's driving distance)\n             placed on patients being considered for this trial. Investigators must assure\n             themselves that the patients registered on this trial will be available for complete\n             documentation of the treatment, adverse events, response assessment and follow-up.\n\n          -  In accordance with NCIC CTG policy, protocol treatment is to begin within 5 working\n             days of patient randomization.\n\n        Exclusion Criteria:\n\n          -  Patients with a history of other malignancies, except for adequately treated\n             non-melanoma skin cancer or solid tumours curatively treated with no evidence of\n             disease for > 3 years. (Please call NCIC CTG if any questions about the\n             interpretation of this criterion).\n\n          -  Patients who are on immunosuppressive therapy or have known HIV infection or active\n             hepatitis B or C.\n\n          -  Patients with active or uncontrolled infections or with serious illnesses or medical\n             conditions which would not permit the patient to be managed according to the\n             protocol.\n\n          -  Patients with significant cardiac (including uncontrolled hypertension) or pulmonary\n             disease, or active CNS disease or infection.\n\n          -  Patients are not eligible if they have a known hypersensitivity to the study drug(s)\n             or their components.\n\n          -  Patients with history of central nervous system metastases or untreated spinal cord\n             compression.\n\n          -  Patients who have contraindications to treatment with paclitaxel and/or neuropathy >\n             grade 1.\n\n          -  Women must be post-menopausal, surgically sterile or use two reliable forms of\n             contraception while on study and for 6 months after discontinuing therapy. Women of\n             childbearing potential must have a pregnancy test taken and proven negative within 7\n             days prior to randomization and must not be lactating. Men must be surgically sterile\n             or use a barrier method of contraception.\n\n          -  Concurrent treatment with other investigational drugs or anti-cancer therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656538", 
            "org_study_id": "I213"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Paclitaxel plus Reolysin", 
                    "Paclitaxel"
                ], 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Paclitaxel plus Reolysin", 
                "intervention_name": "Reolysin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Susan Ellard", 
                    "phone": "250 712-3900", 
                    "phone_ext": "686657"
                }, 
                "facility": {
                    "address": {
                        "city": "Kelowna", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V1Y 5L3"
                    }, 
                    "name": "BCCA - Cancer Centre for the Southern Interior"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Karen Gelmon", 
                    "phone": "604 877-6000", 
                    "phone_ext": "2032"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }, 
                    "name": "BCCA - Vancouver Cancer Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Vanessa Bernstein", 
                    "phone": "250 519-5571"
                }, 
                "facility": {
                    "address": {
                        "city": "Victoria", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V8R 6V5"
                    }, 
                    "name": "BCCA - Vancouver Island Cancer Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sukhbinder Dhesy-Thind", 
                    "phone": "905 387-9495", 
                    "phone_ext": "64431"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }, 
                    "name": "Juravinski Cancer Centre at Hamilton Health Sciences"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mihaela Mates", 
                    "phone": "613 549-2631", 
                    "phone_ext": "4503"
                }, 
                "facility": {
                    "address": {
                        "city": "Kingston", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K7L 5P9"
                    }, 
                    "name": "Cancer Centre of Southeastern Ontario at Kingston"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Susan Dent", 
                    "phone": "613 737-7700", 
                    "phone_ext": "70167"
                }, 
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H 8L6"
                    }, 
                    "name": "Ottawa Hospital Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nathaniel Bouganim", 
                    "phone": "514 398-8307"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2W 1S6"
                    }, 
                    "name": "McGill University - Dept. Oncology"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Vamsee Torri", 
                    "phone": "306 766-2691"
                }, 
                "facility": {
                    "address": {
                        "city": "Regina", 
                        "country": "Canada", 
                        "state": "Saskatchewan", 
                        "zip": "S4T 7T1"
                    }, 
                    "name": "Allan Blair Cancer Centre"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "lseymour@ctg.queensu.ca", 
            "last_name": "Lesley Seymour", 
            "phone": "613-533-6430"
        }, 
        "overall_official": [
            {
                "affiliation": "BCCA - Vancouver Island Centre", 
                "last_name": "Vanessa Bernstein", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "BCCA-Cancer Ctr., Southern Interior", 
                "last_name": "Susan Ellard", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656538"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To investigate additional potential measures of efficacy including Objective response rate, overall survival (OS) and CTC counts.", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Potential molecular factors predictive of response by assessment of archival tumour tissue and CTCs (including EGFR and KRAS status) and serial blood samples", 
                "measure": "Tumour and tissue response of potential molecular factors", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "To determine the tolerability and toxicity of reolysin and paclitaxel when given in combination.", 
                "measure": "Number of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "NCIC Clinical Trials Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Oncolytics Biotech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "NCIC Clinical Trials Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}